TGFB1 and neoplasm: Another bifunctional TGF-β trap fused drug, anti-CTLA4-TGF-βRII, showed superior anti-tumour efficacy compared to an anti-CTLA4 antibody alone in preclinical models [336], but its efficacy in patients has not been investigated.